Case ReportsJ Subst Abuse Treat
. 2022 Jul:138:108717.
doi: 10.1016/j.jsat.2021.108717. Epub 2021 Dec 30.
Patrick Köck 1, Katharina Froelich 2, Marc Walter 2, Undine Lang 2, Kenneth M Dürsteler 3
Affiliations Expand
- PMID: 35012793
- DOI: 10.1016/j.jsat.2021.108717
Free article
A systematic literature review of clinical trials and therapeutic applications of ibogaine
Abstract
Background: Iboga and its primary alkaloids, ibogaine and noribogaine, have been of interest to researchers and practitioners, mainly due to their putative efficacy in treating substance use disorders (SUDs). For many SUDs, still no effective pharmacotherapies exist. Distinct psychoactive and somatic effects of the iboga alkaloids set them apart from classic hallucinogens like LSD, mescaline, and psilocybin.
Aims: The study team performed this systematic review focusing on clinical data and therapeutic interventions involving ibogaine and noribogaine.
Methods: The team conducted a search for all publications up to December 7, 2020, using PubMed and Embase following PRISMA guidelines.
Results: In total, we identified 743 records. In this review, we consider 24 studies, which included 705 individuals receiving ibogaine or noribogaine. This review includes two randomized, double-blind, controlled clinical trials, one double-blind controlled clinical trial, 17 open-label studies or case series (including observational or retrospective studies), three case reports, and one retrospective survey. The published data suggest that ibogaine is an effective therapeutic intervention within the context of SUDs, reducing withdrawal symptoms and craving. Data also point toward a beneficial impact on depressive and trauma-related psychological symptoms. However, studies have reported severe medical complications and deaths, which seem to be associated with neuro- and cardiotoxic effects of ibogaine. Two of these fatalities were described in the 24 studies included in this review.
Conclusion: Treatment of SUDs and persisting comorbidities requires innovative treatment approaches. Rapid-onset therapies such as the application of ibogaine may offer novel treatment opportunities for specific individuals. Rigorous study designs within medical settings are necessary to warrant safe application, monitoring, and, possibly, medical intervention.
Keywords: Cocaine; Hallucinogen; Opioid; Psychedelic; Substance use disorder; Treatment.
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Similar articles
- Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A Systematic Review of the Current Literature.Mosca A, Chiappini S, Miuli A, Mancusi G, Santovito MC, Di Carlo F, Pettorruso M, Corkery JM, Canessa C, Martinotti G, Di Giannantonio M.Curr Neuropharmacol. 2023;21(11):2178-2194. doi: 10.2174/1570159X21666221017085612.PMID: 36263479Free PMC article.
- IUPHAR – invited review – Ibogaine – A legacy within the current renaissance of psychedelic therapy.Mash DC.Pharmacol Res. 2023 Apr;190:106620. doi: 10.1016/j.phrs.2022.106620. Epub 2023 Mar 11.PMID: 36907284Review.
- Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview.Ona G, Reverte I, Rossi GN, Dos Santos RG, Hallak JE, Colomina MT, Bouso JC.J Psychopharmacol. 2023 Dec;37(12):1190-1200. doi: 10.1177/02698811231200882. Epub 2023 Nov 8.PMID: 37937505Review.
- Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine.Malcolm BJ, Polanco M, Barsuglia JP.J Psychoactive Drugs. 2018 Jul-Aug;50(3):256-265. doi: 10.1080/02791072.2018.1447175. Epub 2018 Apr 2.PMID: 29608409
- Psychedelic Therapy: A Primer for Primary Care Clinicians-Ibogaine.Cherian K, Shinozuka K, Tabaac BJ, Arenas A, Beutler BD, Evans VD, Fasano C, Muir OS.Am J Ther. 2024 Mar-Apr 01;31(2):e133-e140. doi: 10.1097/MJT.0000000000001723.PMID: 38518270
Cited by
- Evolution and Comparative Analysis of Clinical Trials on Psilocybin in the Treatment of Psychopathologies: Trends in the EU and the US.Calin A, Burlec AF, Mircea C, Macovei I, Hancianu M, Corciova A.J Clin Med. 2025 Sep 19;14(18):6613. doi: 10.3390/jcm14186613.PMID: 41010814Free PMC article.
- 5-HT2A Receptor Knockout Mice Show Sex-Dependent Differences following Acute Noribogaine Administration.Villalba S, González B, Junge S, Bernardi A, González J, Fagúndez C, Torterolo P, Carrera I, Urbano FJ, Bisagno V.Int J Mol Sci. 2024 Jan 5;25(2):687. doi: 10.3390/ijms25020687.PMID: 38255760Free PMC article.
- The CAnadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT): A Multi-Phase Program Overview.Carlson LE, Richardson H, Shore R, Albertyn CP, Balneaves LG, Bates A, Burnell M, Chochinov HM, Clements D, Deleemans J, Horlock H, Mathews J, McKenzie M, Savard C, Soares CN, Tu W, Williams M.Curr Oncol. 2025 Dec 22;33(1):7. doi: 10.3390/curroncol33010007.PMID: 41590327Free PMC article.Review.
- Psychedelics and chronic pain: self-reported outcomes on changed substance use patterns and health following naturalistic psychedelic use.Glynos NG, Baker A, Aday JS, Kruger D, Boehnke KF, Lake S, Lucas P.Br J Pain. 2025 Jun;19(3):187-199. doi: 10.1177/20494637251319497. Epub 2025 Feb 11.PMID: 39944237Free PMC article.
- Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions.Guidetti C, Fava M, Papakostas GI.Mol Psychiatry. 2026 Jun 25. doi: 10.1038/s41380-026-03722-0. Online ahead of print.PMID: 42350785Review.
Publication types
MeSH terms
- Alkaloids* / therapeutic use
- Hallucinogens* / adverse effects
- Humans
- Ibogaine* / adverse effects
- Observational Studies as Topic
- Randomized Controlled Trials as Topic
- Retrospective Studies
- Substance Withdrawal Syndrome* / drug therapy
- Substance-Related Disorders* / drug therapy
No responses yet